Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.

Acta Pharmacologica Sinica
Yang LvGang Hu

Abstract

Increasing preclinical evidence demonstrates that dopamine D3 receptor (D3R) antagonists are a potential option for the treatment of drug addiction. The reinstatement of the addiction can be triggered by environmental stimuli that acquire motivational salience through repeated associations with the drug's effects. YQA14 is a novel D3R antagonist that has exhibited pharmacotherapeutic efficacy in reducing cocaine and amphetamine reward and relapse to drug seeking in mice. In this study we investigated the effects of YQA14 on morphine-induced context-specific locomotor sensitization in mice. We showed that repeated injection of YQA14 (6.25-25 mg/kg every day ip) prior to morphine (10 mg/kg every day sc) not only inhibited the acquisition, but also significantly attenuated the expression of morphine-induced locomotor sensitization. Furthermore, in the expression phase, one single injection of YQA14 (6.25-25 mg/kg, ip) dose-dependently inhibited the expression of morphine-induced behavioral sensitization. Moreover, YQA14 inhibited the expression of morphine-induced behavioral sensitization in wild mice (WT), but not in D3R knockout (D3R-/-) mice in the expression phase. In addition, D3R-/- mice also displayed the reduction in the e...Continue Reading

References

Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R SpanagelT S Shippenberg
Jan 1, 1991·Physiological Reviews·M Le Moal, H Simon
Mar 1, 1974·Pharmacology, Biochemistry, and Behavior·D S Segal, A J Mandell
Sep 1, 1993·Brain Research. Brain Research Reviews·T E Robinson, K C Berridge
Dec 24, 1997·Brain Research. Brain Research Reviews·R C Pierce, P W Kalivas
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E V Gurevich, J N Joyce
Dec 20, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G F Koob, M Le Moal
Aug 10, 2001·Journal of Long-term Effects of Medical Implants·S L BrownC M Parmentier
Oct 5, 2001·Nature Reviews. Neuroscience·S E Hyman, R C Malenka
Apr 2, 2002·Neuroreport·Harinder AujlaRichard J Beninger
Jul 9, 2002·The European Journal of Neuroscience·Bernard Le FollPierre Sokoloff
Aug 20, 2002·Annual Review of Psychology·Terry E Robinson, Kent C Berridge
Oct 6, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zheng-Xiong XiEliot L Gardner
Sep 7, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter W Kalivas, Charles O'Brien
Feb 1, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jing LiangYingcong Li
Apr 15, 2011·Pharmacological Reviews·Jeffery D Steketee, Peter W Kalivas
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Rui SongZheng-Xiong Xi
Jul 8, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maram A T M KhaledBernard Le Foll
Jun 26, 2015·Journal of Addictive Diseases·David M NovickMary Jeanne Kreek

❮ Previous
Next ❯

Citations

Apr 9, 2021·Peptides·Richard J Bodnar

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

Anilab
Sigma Stat

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.